Vifor Rises Closer to CSL Offer on Settlement of Injectafer Case

Vifor Pharma shares rise as much as 2.1% after the Swiss drug maker and American Regent settle in Injectafer patent case.

• Stock trading 1.6% up to CHF 162.3 as of 9:11 am CET, and against offer price by Australian biotech company CSL of CHF 167
• Vifor and partner American Regent to grant Mylan Laboratories and Sandoz licenses to market generic ferric carboxymaltose products in the U.S. beginning July 1, 2026
• NOTE: Dec, 14: Analyst highlight the litigation involving the Injectafer patent in the U.S. and what happens if Vifor loses
• The unusually substantial spread between Vifor stock price and CSL ...